FREEHOLD, NJ, Feb. 23, 2018 (GLOBE NEWSWIRE) -- MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce that its Time Machine Infrared Laser will be used for a new Sleep Apnea program.
Dr. Glenn A. MacFarlane D.M.D., based in New Jersey, will use the Time Machine Infrared Laser as part of the treatment protocol for his Sleep Apnea Silent Sleep Rx program that is affiliated with many prominent healthcare centers and private practices.
Dr. MacFarlane is very passionate about Holistic Dentistry and he will be hosting educational training events on Holistic Dentistry. These events will feature Sleep Apnea education and introduce his Silent Sleep Rx program which includes the Time Machine Infrared Laser and training courses. Dental professionals throughout the country can join the network and implement the Silent Sleep Rx program and the Time Machine Laser into their practice. The benefits are new revenue streams and effective holistic treatment modalities and solutions to better serve their patients. Dr. MacFarlane’s practice located in Red Bank, NJ includes the Time Machine Laser treatments for TMD.
Sleep disorders, including Sleep Apnea, have become a significant health issue in the United States. It is estimated that 42 million Americans suffer from Sleep Apnea, with 80 percent of the cases of moderate and severe obstructive Sleep Apnea undiagnosed. Many lawmakers are proposing legislation to have state and federal transit workers and truck drivers tested for this disorder. Recently, the National Transportation Safety Board reported that the probable cause of the 2016 NJ Transit crash at the Hoboken rail terminal, in which a train accelerated as it was coming into the station, was “the engineer’s fatigue resulting from his undiagnosed severe obstructive sleep apnea.”
Dr. MacFarlane is an aesthetic focused dentist, and has been dedicated for almost 30 years now to brightening thousands of smiles. He has memberships in several prestigious organizations including the American Dental Association (national, state and county), the Academy of General Dentistry, the American Academy of Cosmetic Dentistry, the Academy of Laser Dentistry, the American Academy of Facial Esthetics, the Academy of Comprehensive Esthetics, the American Academy of Implant Dentistry and the American Academy of Dental Sleep Medicine.
Medifirst anticipates further announcements in the upcoming days and weeks on additional company developments which will include updates on blockchain technology and new expanding services.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.
Forward-Looking Statements:
The statements in this press release that relate to the company’s expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.